BBP-398

SHP2 inhibitor for MAPK/RAS driven cancers

estimated prevalence

>500,000

Disease

MAPK/RAS driven cancers

Genetic Source

PTPN11 (SHP2) and MAPK pathway

Clinical Phase

Phase 1

Modality

small molecule

our science

our science icon icon

our approach icon icon

patient resources icon icon